Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity

Immunology

Volumn 120, Issue 1, 2007, Pages 90-102

  Hao, Siguo ^a   Bai, Ou ^a   Li, Fang ^a   Yuan, Jinying ^a   Laferte, Suzanne ^b   Xiang, Jim ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c SASKATCHEWAN CANCER AGENCY   (Canada)

Author keywords

Antitumour immunity; Cytotoxic T lymphocyte; Dendritic cell; Exosome; Vaccine

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 33845677330     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2006.02483.x     Document Type: Article

References (46)

1. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003; 425 (6956):397-402.
2. Kleijmeer MJ, Escola JM, UytdeHaag FG et al. Antigen loading of MHC class I molecules in the endocytic tract. Traffic 2001; 2:124-37.
3. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996; 183:1161-72.
4. Zitvogel L, Regnault A, Lozier A et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4:594-600.
5. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113:3365-74.
6. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998; 273 (32):20121-7.
7. Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, Newman GR, Jasani B. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Meth 2001; 247 (1-2):163-74.
8. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Meth 2002; 270:211-26.
9. Andreola G, Rivoltini L, Castelli C et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002; 195:1303-16.
10. Altieri SL, Khan AN, Tomasi TB. Exosomes from plasmacytoma cells as a tumor vaccine. J Immunother 2004; 27:282-8.
11. Wolfers J, Lozier A, Raposo G et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7:297-303.
12. Andre F, Schartz NE, Movassagh M et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002; 360 (9329):295-305.
13. Hsu DH, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E, Zitvogel L, Le Pecq JB. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J Immunother 2003; 26:440-50.
14. Andre F, Chaput N, Schartz NE et al. Exosomes as potent cellfree peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004; 172:2126-36.
15. Chaput N, Schartz NE, Andre F et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 2004; 172:2137-46.
16. Cho JA, Yeo DJ, Son HY et al. Exosomes: a new delivery system for tumor antigens in cancer immunotherapy. Int J Cancer 2005; 114:613-22.
17. Escudier B, Dorval T, Chaput N et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 2005; 3:10.
18. Morse MA, Garst J, Osada T et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005; 3:9.
19. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3:1156-62.
20. Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D, Pain S, Raposo G, Benaroch P, Bonnerot C. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol 2002; 14:713-22.
21. Chen Z, Dehm S, Bonham K, Kamencic H, Juurlink B, Zhang X, Gordon JR, Xiang J. DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol 2001; 214:60-71.
22. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 2004; 199:227-50.
23. Slingluff CL Jr. Tumor antigens and tumor vaccines: peptides as immunogens. Semin Surg Oncol 1996; 12:446-53.
24. Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, Carbone FR, Heath WR. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001; 166:6099-103.
25. Zhang W, Chen Z, Li F, Kamencic H, Juurlink B, Gordon JR, Xiang J. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and antitumour immunity than DCs generated in recombinant TNF-alpha. Immunology 2003; 108:177-88.
26. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997; 6:715-26.
27. Xiang J, Huang H, Liu Y. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper antigen-presenting cells. J Immunol 2005; 174:7497-505.
28. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Meth 1994; 171:131-7.
29. Hao S, Bi X, Xu S, Wei Y, Wu X, Guo X, Carlsen S, Xiang J. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Exp Oncol 2004; 26:300-6.
30. Palucka AK, Dhodapkar MV, Paczesny S, Ueno H, Fay J, Banchereau J. Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. J Immunother 2005; 28:158-68.
31. Drickamer K. C-type lectin-like domains. Curr Opin Struct Biol 1999; 9:585-90.
32. Hwang I, Shen X, Sprent J. Direct stimulation of naive T cells by membrane vesicles from antigen-presenting cells: distinct roles for CD54 and B7 molecules. Proc Natl Acad Sci USA 2003; 100:6670-5.
33. Wang JC, Livingstone AM. Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol 2003; 171 (12):6339-43.
34. Wang LX, Kjaergaard J, Cohen PA, Shu S, Plautz GE. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. J Immunol 2004; 172:3462-8.
35. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol 1998; 16:201-23.
36. Segura E, Amigorena S, Thery C. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cell Mol Dis 2005; 35:89-93.
37. Segura E, Nicco C, Lombard B, Veron P, Raposo G, Batteux F, Amigorena S, Thery C. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 2005; 106:216-23.
38. Quah BJ, O'Neill HC. The immunogenicity of dendritic cell-derived exosomes. Blood Cell Mol Dis 2005; 35:94-110.
39. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675-80.
40. Knight SC, Iqball S, Roberts MS, Macatonia S, Bedford PA. Transfer of antigen between dendritic cells in the stimulation of primary T cell proliferation. Eur J Immunol 1998; 28:1636-44.
41. Cambi A, Gijzen K, de Vries JM et al. The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol 2003; 33:532-8.
42. East L, Isacke CM. The mannose receptor family. Biochim Biophys Acta 2002; 1572:364-86.
43. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, Steinman RM. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000; 151:673-84.
44. Bard MP, Hegmans JP, Hemmes A et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol 2004; 31:114-21.
45. Xiang J, Chen Y, Moyana T. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Cancer Gene Ther 2000; 7:1023-33.
46. Liu Y, Huang H, Chen Z, Zong L, Xiang J. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. J Gene Med 2003; 5:668-80.